期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

托珠单抗治疗类风湿关节炎的专家建议 被引量：11

原文传递
导出
摘要 类风湿关节炎（rheumatoid arthritis，RA）是一种主要累及患者外周关节的慢性炎症性自身免疫病，严重影响患者的生活质量、工作能力和预期寿命。近年来，随着对RA发病机制的不断了解以及诊治水平的提高，RA的治疗模式已经从使用非甾体抗炎药（NSMDs）控制症状逐渐演变为使用改善病情抗风湿药（DMARDs）和生物制剂以减轻炎症、控制疾病进程旧。当前RA的治疗目标是使患者尽早达到疾病的临床缓解或低疾病活动度，生物制剂的应用大大提高了RA治疗的达标率嘲。
作者 张奉春 赵岩 黄烽
机构地区 托珠单抗治疗类风湿关节炎专家组
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2013年第7期436-438,共3页 Chinese Journal of Rheumatology
关键词 类风湿关节炎 单抗治疗 慢性炎症性自身免疫病 专家 非甾体抗炎药 生物制剂 疾病进程 疾病活动度
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献13

  • 1Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther, 2012, 91: 607-620. 被引量：1
  • 2Horton SC, Walsh CA, Emery P. Established rheumatoid arthri- tis: rationale for best practice: physicians' perspective of how to realise tight control in clinical practice. Best Pract Res Clin Rheumatol, 2011, 25: 509-521. 被引量：1
  • 3Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hobo- ken), 2012, 64: 625-639. 被引量：1
  • 4Finckh A, Simard JF, Gabay C, et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis, 2006, 65: 746-752. 被引量：1
  • 5Thalayasingam N, Isaaes JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol, 2011, 25: 549-567. 被引量：1
  • 6Moots RJ, Ostor AJ, Isaacs JD. Win treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remis- sion'? Expert Opin Investig Drugs, 2009, 18: 1687-1699. 被引量：1
  • 7王立,张奉春.白细胞介素-6受体阻滞剂与自身免疫性疾病[J].中华临床免疫和变态反应杂志,2010,4(1):55-60. 被引量：6
  • 8姜楠,费允云,赵岩.白细胞介素-6阻断剂在类风湿关节炎的治疗应用[J].中华临床免疫和变态反应杂志,2012,6(3):232-236. 被引量：17
  • 9Koike R, Harigai M, Atsumi T, et al. Japan College of Rheuma- tology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol, 2009, 19: 351-357. 被引量：1
  • 10Navarro-Mill6n I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent target- ing the interleukin-6 receptor. Clin Ther, 2012, 34: 788-802. 被引量：1

二级参考文献77

  • 1Gaffe A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. A m J Health Syst Pharm,2006,63 : 2451-2465. 被引量：1
  • 2Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis : the interleukin-6 receptor. Rheumatology (Oxford) ,2010,49 : 15-24. 被引量：1
  • 3Nishimoto N, Kishirnoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol,2006 ,2 :619-626. 被引量：1
  • 4Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumato1,2006,33 : 1516-1522. 被引量：1
  • 5Jongen-Lavrencic M, Peeters HR, Rozemuller H, et al. IL-6- induced anaemia in rats: possible pathogenetic implications for anemia observed in chronic inflammations. Clin Exp Immunol, 1996,103:328-334. 被引量：1
  • 6I Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J,2003,374( Pt 1 ) :1-20. 被引量：1
  • 7Genovese MC, McKay JD, Nasonov EL, et al. lnterleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs : the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum,2008,58 : 2968 -2980. 被引量：1
  • 8Emery P, Keystone E, Tony HP, et al, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis,2008,67 : 1516-1523. 被引量：1
  • 9Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor ( SAMURAI ) : evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trim of tocilizumab. Ann Rheum Dis,2007,66 : 1162-1167. 被引量：1
  • 10Hashimoto J, Garnero P, Miyasaka N, et al. Early changes in biochemical markers of cartilage turnover and synovial inflammation predict the effects of tocilizumab monotherapy on one- year radiographic progression in patients with early rheumatoid arthritis [ abstract 1. Arthritis Rheum, 2006,54 Suppl : $410. 被引量：1

共引文献47

同被引文献97

  • 1王利军,杨林花,李小峰.细胞因子在类风湿关节炎血小板升高机制中的作用及研究进展[J].中华风湿病学杂志,2005,9(1):53-55. 被引量：12
  • 2王春淮,徐建华.利妥昔单抗治疗类风湿关节炎研究进展[J].中华风湿病学杂志,2005,9(6):367-369. 被引量：2
  • 3Abdel Meguid MH, Hamad YR, Swilam RS, et al. Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage [J]. Rheumatol Int, 2013, 33 (3): 697-703. 被引量：1
  • 4Kimura A, Kishimoto T. IL-6: regulator of Treg/Th 17 balance [J]. Eur J Immunol, 2010, 40(7): 1830-1835. 被引量：1
  • 5Eulenfeld R, Dittrich A, Khouri C, et al. Interleukin-6 signalling: more than Jaks and STATs [J]. Eur J Cell Bioi, 2012,91 (6-7): 486-495. 被引量：1
  • 6Hashizume M, Hayakawa N, Suzuki M, et al. IL-6/sIL-6R trans-signalling, but not TNF-a induced angiogenesis in a HUVEC and synovial cell co-culture system [J]. Rheumatol Int, 2009, 29 (12): 1449-1454. 被引量：1
  • 7Suzuki M, Hashizume M, Yoshida H, et al. Antiinflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule[J]. Rheumatol Int, 2010, 30 (3): 309-315. 被引量：1
  • 8Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF -a and IL-17 [J] . Rheumatology, 2008, 47 (11): 1635-1640. 被引量：1
  • 9Hashizume M, Mihara M. Desirable effect of combination therapy with high molecular weight hyaluronate and NSAIDs on MMP production [J]. Osteoarthritis Cartilage, 2009, 17(1I): 1513-1518. 被引量：1
  • 10Suzuki M, Hashizume M, Yoshida H, et al. IL-6 and IL-l synergistically enhanced the production of MMPs fromsynovial cells by up-regulating IL-6 production and IL-I receptor I expression[J]. Cytokine, 2010, 51 (2): 178-183. 被引量：1

引证文献11

二级引证文献67

中华风湿病学杂志
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部